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Background: Complementary and alternative herbal medicines are recently considered as a promising approach
for treating various diseases. We screened approximately 100 plant extracts for anti-allergic activity. Rhamnus davurica
leaf extract showed the most potent inhibitory effect on the activation of RBL-2H3 mast cells. Although Rhamnus
davurica extract has been used to treat pruritus, dysuresia, and constipation as a traditional herbal medicine in
some Asian countries, an anti-allergic effect of Rhamnus davurica has not yet been demonstrated. We aimed to
investigate the effect and mechanism of the leaf extract of Rhamnus davurica (LERD) on mast cells in vitro and
allergic responses in vivo.
Methods: The effects of LERD on the activation of mast cells and mast cell-mediated passive cutaneous anaphylaxis
(PCA) were measured in mice and two types of mast cells, mouse bone marrow-derived mast cells (BMMCs) and
RBL-2H3 cells in vitro. A mechanistic study of its inhibitory effect was performed by using degranulation assay,
reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, and western blotting analysis.
Results: LERD reversibly suppressed antigen-stimulated degranulation in BMMCs and RBL-2H3 cells, and also inhibited
mRNA expression and secretion of TNF-α and IL-4 in a dose-dependent manner. In a PCA animal model, LERD
significantly inhibited antigen-induced allergic response and degranulation of ear tissue mast cells. As for the
mechanism of action, LERD inhibited the activation of Syk, which is the pivotal signaling protein for mast cell
activation by antigen. Furthermore, LERD also impeded the activations of well-known downstream proteins such
as LAT, Akt and three MAP kinases (Erk, p38 and JNK). In an in vitro kinase assay, LERD suppressed the activation of
Fyn in antigen-stimulated mast cells.
Conclusion: This study demonstrated for the first time that LERD has anti-allergic effects through inhibiting the
Fyn/Syk pathway in mast cells. Therefore, this study provides scientific evidence for LERD to be used as an herbal
medicine or health food for patients with allergic diseases.
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Allergic diseases such as allergic asthma, allergic rhinitis,
and atopic dermatitis have been increasing, particularly
in many developed countries. Generally, around 10 to
20% of the population are reported as presenting with
allergic diseases in those countries [1,2]. Usually, patients
with allergy-prone genetic factors have type 2 helper T
cells (Th2) reactions under a certain environment. When
patients are exposed to potential allergens such as milk,
egg, nuts, and shellfish, various allergic symptoms may
occur. In the course of early and late allergic reactions,
mast cells are solidly acknowledged as one of the major
culprit effector cells [3].
Mast cells play a key role in prompting a variety of
allergic symptoms [4,5]. Mast cells have FcεRI, a high-
affinity receptor for IgE, which makes a complex with
antigen-specific IgE. When mast cells are stimulated by
an antigen, various allergic mediators including hista-
mines, eicosanoids, and pro-inflammatory cytokines are
secreted from mast cells [6,7]. Thus, mast cells play a
critical role in causing allergic diseases, and therefore
mast cells-stabilizing therapies have been increasingly
reported [8,9].
When mast cells are stimulated by antigens, the initial
activation of Lyn or other Src-family kinases is observed
for the phosphorylation of an immunoreceptor tyrosine
activation motif (ITAM) of FcεRI γ subunit and Syk is,
then, recruited to tyrosine phosphorylated ITAMs for the
full activation of Syk [10,11]. This event leads to the acti-
vation of downstream signaling molecules including a
linker for the activation of T cells (LAT), SLP-76, Gab2,
phospholipase (PL) Cγ, and MAP kinases. This series of
activations of signaling proteins leads to the full activation
of mast cells in prompting allergic responses [12,13].
The Src family kinases, including Lyn, Fyn, and Fgr,
are activated by antigen stimulation in mast cells [11].
The initial activation of Lyn is essential for the activation
of mast cells, and Lyn additionally also has a negative
role in mitigating the excess activation of mast cells [14].
Whereas Fyn and Fgr show solely a positive role in the
activation of Syk and its downstream signaling cascades
for mast cell activation [11]. Therefore, a Src-family
kinase-targeted study could be an efficient direction for
treatment of allergic diseases.
Rhamnus davurica is widely found throughout fields
of Korea, China, and other Asian countries. Extract of
Rhamnus davurica has long been in use as a folk remedy
in the treatment of several diseases including pruritus, dys-
uresia, and constipation. However, the effect of Rhamnus
davurica on allergic diseases remains to be unclear.
In this study, we investigated the anti-allergic effects
of the leaf extract of Rhamnus davurica (LERD) in mast
cells cultures and in passive cutaneous anaphylaxis animal
models. LERD suppressed the activation of mast cells andanaphylaxis responses through the inhibition of the activa-
tion of Fyn/Syk pathway in antigen-stimulated mast cells.
Methods
Reagents
Antibodies that work against the phosphorylated forms
of Akt, Erk1/2, p38, JNK, Syk (Y525/526), and LAT
(Y191) were obtained from Cell Signaling Technology, Inc.
(Danvers, MA, USA). The 4-Amino-5-(4-chlorophenyl)-
7-(dimethylethyl)pyrazolo [3,4-d]pyrimidine (PP2) was
obtained from Calbiochem (La Jolla, CA, USA). Enzyme-
linked immunosorbant assay (ELISA) kits for analyzing
IL-4 in media was obtained from Invitrogen-Biosource
Cytokine & Signaling (Camarillo, CA, USA). An ELISA
kit for TNF-α measurement was from R&D Systems,
Inc. (Minneapolis, MN, USA). Reagents for cell culture
media were obtained from GIBCO/Life Technologies,
Inc. (Rockville, MD, USA). Most of all the other reagents
used were purchased from Sigma-Aldrich (St. Louis,
MO, USA).
Animals
BALB/c mice (5-weeks old) were used for the isolation of
bone marrow-derived mast cells (BMMCs) and the induc-
tion of passive cutaneous anaphylaxis (PCA). All animal
studies were performed according to institutional guidelines
after obtaining approval from the Institutional Animal Care
and Use Committee (IACUC) at Konkuk University.
Mast cell preparation and cell culture
BMMCs were isolated from the thigh bones of 5 week-
old BALB/c mice as in previous studies [15]. The
BMMCs were cultured in media (RPMI 1640), contain-
ing 2 mM L-glutamine, 0.1 mM nonessential amino
acids, antibiotics, and 10% fetal bovine serum (FBS) con-
taining 10 ng/ml IL-3 in 5% CO2, 37°C incubator. Four
weeks following isolation, the BMMCs were used for the
following experiments. The RBL-2H3 cells from ATCC
(American Type Culture Collection, VA, USA) were
cultured in a minimum essential medium (MEM) with
Earle’s salts, supplemented with glutamine, antibiotics,
and 15% FBS.
Preparation of LERD and other plant extracts
Leaf of Rhamnus davurica was collected from Hantaek
Botanical Garden (Yongin-si, Korea) and was authenti-
cated by the Plant Extract Bank at the Korea Research
Institute of Bioscience and Biotechnology (Daejeon, Korea).
The methanol extracts of Rhamnus davurica leaf (LERD)
and other plants were manufactured according to the
institute’s standard protocol. The yield of the extraction
process was approximately 15% of total dry leaf amount.
The extracted and plant specimen (017-005 for LERD
or as indicated in Table 1) were deposited at the Plant
Table 1 Effects of plant extracts on the Ag-induced degranulation in RBL-2H3 mast cells
Plant name Part extracted Voucher specimen number Percent inhibition of degranulationa
Acer okamotoanum Stem-bark 016-081 0.00
Acer ukurunduense Leaf 016-050 40.78
Acer ukurunduense Stem 016-051 30.32
ActinoStemma lobatum Whole plant 017-038 18.48
Ardisia pusilla Whole plant 016-061 0.00
Aster incisa Whole plant 016-001 0.00
Berberis amurensis var. quelpaertensis Stem 016-069 16.96
Betula chinensis Leaf 017-013 39.17
Betula chinensis Stem 017-014 27.76
Betula davurica Stem 017-045 3.78
Betula davurica Stem-bark 017-046 0.00
Betula ermani var. saitoana Leaf 016-089 10.80
Betula ermani var. saitoana Stem 016-090 1.78
Boehmeria pannosa Whole plant 016-080 0.43
Bupleurum longeradiatum Whole plant 017-016 29.22
Cacalia auriculata var. matsumurana Whole plant 016-047 12.05
Campylotropis macrocarpa Aboveground part 017-023 0.00
Celosia argentea Whole plant 017-012 38.14
Chaenomeles sinensis Leaf 017-040 3.85
Cinnamomum loureirii Leaf 016-082 5.92
Clerodendrum trichotomum Leaf 016-026 2.27
Clintonia udensis Whole plant 016-019 51.37
Corydalis heterocarpa Whole plant 016-079 11.79
Crataegus scabrida fruit 017-047 0.00
Cyrtomium falcatum Aboveground part 016-028 4.84
Daphniphyllum macropodum Leaf 017-019 6.46
Daphniphyllum macropodum Stem 017-020 0.29
Deutzia prunifolia Stem 017-051 44.69
Dicentra spectabilis Aboveground part 016-010 8.22
Diospyros kaki Leaf 017-007 17.98
Diospyros kaki Stem 017-008 17.68
Diospyros kaki Stem-bark 017-009 17.25
Diospyros kaki Root 017-011 11.64
Dryopteris championi Whole plant 016-088 6.97
Elaeagnus macrophylla Leaf 017-059 23.52
Forsythia nakaii Leaf 016-085 1.93
Fraxinus sieboldiana Leaf 017-073 9.30
Geranium wilfordii Whole plant 017-070 42.07
Houttuynia cordata Whole plant 016-077 7.45
Hydrangea serrata for. acuminata Aboveground part 016-058 67.16
Hypericum erectum Whole plant 017-018 6.53
Kalopanax pictus Stem-heartwood 016-083 14.84
Lilium lancifolium Aboveground part 016-091 8.82
Lindera erythrocarpa Leaf 016-054 18.09
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Lindera erythrocarpa Stem 016-055 14.20
Lindera obtusiloba Stem 016-063 19.80
Lycopodium clavatum var. nipponicum Whole plant 017-069 23.56
Lycoris aurea Underground part 017-015 52.03
Melandryum seoulense Whole plant 017-003 62.76
Monochoria vaginalis var. plantaginea Whole plant 017-043 2.84
Mosla punctulata Whole plant 017-037 6.83
Nandina domestica Leaf 016-023 6.46
Nuphar japonicum Whole plant 016-006 9.22
Oenothera laciniata Whole plant 016-075 14.50
Pedicularis resupinata Whole plant 017-072 35.15
Perilla frutescens var. acuta Whole plant 017-071 14.14
Persicaria fauriei Whole plant 018-003 28.89
Persicaria thunbergii Whole plant 017-017 17.79
Phlomis koraiensis Aboveground part 017-064 19.72
Phlomis koraiensis Underground part 017-065 1.94
Phtheirospermum japonicum Whole plant 017-024 27.81
Picris hieracioides var. glabrescens Whole plant 017-074 16.13
Polystichum polyblepharum Whole plant 016-020 0.99
Potentilla dickinsii Whole plant 017-036 7.18
Prunus sargentii Leaf 017-062 24.50
Prunus takesimensis Stem-bark 016-070 52.74
Pyrus pyrifolia Leaf 017-034 3.85
Pyrus pyrifolia Stem-bark 017-035 11.10
Rhamnus davurica Leaf 017-005 92.35
Rhododendron tschonoskii Leaf 016-099 9.43
Rhododendron tschonoskii Stem 016-100 25.70
Rhododendron yedoense var. poukhanense Stem 016-060 16.80
Rhodotypos scandens Leaf 017-056 14.20
Rodgersia tabularis Whole plant 016-005 3.83
Salix hallaisanensis Stem 016-036 31.12
Sanguisorba hakusanensis Whole plant 017-068 10.22
Sanguisorba tenuifolia var. alba Whole plant 017-002 29.37
Sorbus commixta Stem-bark 016-037 22.84
Sorbus commixta Leaf 016-038 10.86
Sorbus commixta Stem 016-039 14.46
Sorbus commixta fruit 017-039 10.32
Spiraea salicifolia Leaf 016-016 0.00
Stipa sibirica Whole plant 017-025 46.66
Suaeda asparagoides Whole plant 017-026 27.48
Symplocos coreana Stem 016-067 3.90
Syringa velutina Leaf 016-093 0.55
Syringa velutina Stem 016-094 0.35
Tilia insularis Stem-bark 016-071 10.69
Tripterygium regelii Stem 017-048 31.59
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Ulmus laciniata Stem-bark 016-022 0.00
Veronica kiusiana Whole plant 017-028 3.07
Veronica longifolia Aboveground part 017-022 4.14
Viburnum sargentii Leaf 017-052 4.31
Vicia amoena Whole plant 017-006 27.44
Vicia angustifolia var. minor Whole plant 017-001 17.50
Vicia unijuga Whole plant 017-027 28.89
Vitex rotundifolia Leaf 017-075 0.63
Vitis thunbergii var. sinuata Whole plant 016-014 0.11
Zizyphus jujuba fruit 017-042 0.00
aThe degranulation was assessed through the measurement of the release of the granule marker β-hexosaminidase from RBL-2H3 mast cells as described in the
“Methods” section. The percent inhibition of degranulation is presented as the mean values from three independent experiments.
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solubilized in dimethyl sulfoxide (DMSO) for cell culture
experiments and suspended in 5% Gum arabic for oral
administration of extracts in the animal study.
Degranulation assay in mast cells
Mast cells (1.8 × 105/well) were primed in 50 ng/ml
anti-dinitrophenol (DNP) IgE on 24-well plates for
12 h. The cells were then washed twice with 1,4-
piperazinediethanesulfonic acid (PIPES)-buffered medium
[25 mM PIPES (pH 7.2), 159 mM NaCl, 5 mM KCl,
0.4 mM MgCl2, 1 mM CaCl2, 5.6 mM glucose, and 0.1%
fatty acid-free fraction V from bovine serum] for RBL-2H3
cells or with Tyrode buffer [20 mM HEPES (pH 7.4),
135 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2,
5.6 mM glucose, and 0.05% bovine serum albumin (BSA)]
for BMMCs and then pre-incubated in the buffer for 1 h
with or without each plant extract. The mast cells were
stimulated by the antigen (DNP-BSA) for 10 min and
the stimulation was terminated using ice. The cultured
media were transferred to new tubes and cells were dis-
rupted with 0.1% triton X-100. For β-hexosaminidase
assay, the culture media and cell lysates were mixed
with 1 mM p-nitrophenyl-N-acetyl-β-D-glucosaminide
on 96 well plates and incubated at 37°C for 1 h. Next,
0.1 M carbonate was used to stop the reaction. The
density of the color was measured at 405 nm by a
microplate reader. Degranulation of mast cells was
determined by calculating the ratio of β-hexosaminidase
activity released into the culture medium to the total
activity of β-hexosaminidase from the cell lysate plus
the culture medium [16].
Assay of cell viability
BMMCs (5 × 104/well) were plated on 96-well plates in
serum-free RPMI-1640 medium with or without LERD
for 8 h. Then, cell viability was determined by usinga cell counting kit-8 (CCK-8) (Dojindo Laboratories,
Kumamoto, Japan), according to the manufacturer's
protocol. CCK-8 solution was added to each well of the
plate at 1:10 ratio to volume of medium, and the plates
were incubated for 1 h in a CO2 incubator at 37°C. The
absorbance of color density was measured at 450 nm.
Measurement of TNF-α and IL-4 expression by reverse
transcriptase-polymerase chain reaction (RT-PCR)
To obtain the total RNA from cells, an Easy-spinTM
Total RNA Extraction Kit (iNtRON Biotechnology, Inc.,
Sungnam, Korea) was used. PCR was performed at 94°C
for 20 sec, at 62°C for 10 sec, and at 72°C for 20 sec for
30 cycles. The primers were used as follows: rat TNF-α
forward 5′-ACCACGCTCTTCTGTCTACTGAAC-3′; rat
TNF-α reverse: 5′-CCGGACTCCGTGATGTCTAAGTA
CT-3′; rat IL-4 forward 5′-ACCTTGCTGTCACCCTG
TTC-3′; rat IL-4 reverse 5′-TTGTGAGCGT GGACT
CATTC-3′; rat glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) forward 5′-GTGGAGTCTACTGGCGTC
TTC-3′; rat GAPDH reverse: 5′-CCAAGGC TGTGGGC
AAGGTCA-3′.
Measurement of TNF-α and IL-4 in culture media by ELISA
RBL-2H3 cells (5.0 × 105/well/12 well-clustered plate)
were plated with 50 ng/ml DNP-specific IgE overnight.
Cells were stimulated by antigen with or without LERD
for 8 h at 37°C and then the culture media were ana-
lyzed via the ELISA kit according to manufacturer’s
protocol.
Immunoblotting analysis
The IgE-primed RBL-2H3 cells were stimulated with
25 ng/ml antigen for 7 min or as indicated. The cells
were lysed with ice-cold lysis buffer (20 mM HEPES,
pH 7.5, 150 mM NaCl, 1% Nonidet p-40, 10% glycerol,
60 mM octyl β-glucoside, 10 mM NaF, 1 mM Na3VO4,
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nylphosphate, 0.7 μg/ml pepstatin and protease inhibitor
cocktail tablet). Lysates were kept on ice for 30 min and
then centrifuged at 13,000 × g for 10 min at 4°C. After
centrifuging, the supernatant proteins were denatured at
95°C for 5 min in a 3× Laemmli buffer [17]. The dena-
tured proteins were separated by sodium dodecylsulfate
(SDS)-polyacrylamide gel electrophoresis (PAGE) and
then transferred to a nitrocellulose membrane. The
transferred protein membrane was blocked in tris-
buffered saline-0.05% Tween 20 (TBS-T) buffer contain-
ing 5% BSA. The membrane was incubated overnight
with the specific antibody for the target protein. After
washing the membrane with TBS-T buffer, it was incu-
bated with a labeled secondary antibody directed against
the primary antibody. The protein bands for immunore-
active proteins were detected with horseradish peroxid-
ase (HRP)-coupled secondary antibodies and enhanced
chemiluminescence according to manufacturer’s proto-
col (Amersham Biosciences, Piscataway, NJ, USA).
Passive cutaneous anaphylaxis (PCA) and histological
analysis
PCA was generated in mice according to a previous
study [18]. DNP-specific IgE (0.5 μg per mouse) was
intradermally injected into the right ear of a BALB/c
mouse (male, 5 weeks old). After 24 h, LERD (0, 100,A
C
Figure 1 LERD reversibly inhibits antigen-stimulated degranulation in
overnight in 24-well cluster plates with 50 ng/ml of IgE in a complete grow
(25 ng/ml) with or without LERD. The activity of β-hexosaminidase was me
pre-incubated for 1 h with 0.1% DMSO or 100 μg/ml LERD. After LERD-trea
mast cells was measured as for panel A. (D) BMMCs were incubated with L
the “Methods” section. The mean ± SEM from three independent experime
controls, *P < 0.05 and **P < 0.01. PP2 is a general Src family kinase inhibito300, and 1,000 mg/kg) or cetirizine (20 mg/kg) was
orally administered to the mice. After 60 min, the mice
were intravenously injected with 250 μg of antigen in
Evans blue solution (5 mg/ml PBS). The ears were
collected after the mice were euthanized 1 h later. The
dye of ear tissue was extracted overnight in 700 μl of
formamide at 63°C and then the absorbance was ana-
lyzed at 620 nm. For histological analysis, ear tissues
were fixed in 4% paraformaldehyde in PBS for 24 h. 5-μm
paraffin sections were stained with 0.1% toluidine blue
and examined with an optical microscope (Olympus DP
70, Center Valley, PA, USA) at × 100 magnification.
Degranulated mast cells in the ear tissue were counted
as previously described [19].
Measurement of tyrosine kinase activity in vitro
After stimulating IgE-primed mast cells with 25 ng/ml
antigen for 7 min, Lyn or Fyn were immunoprecipitated
from whole cell lysates by using specific antibodies. The
activity of tyrosine kinase was measured using a Universal
Tyrosine Kinase Assay Kit (Gen Way, San Diego, USA)
according to manufacturer’s instruction.
Presentation of results
The data were presented as the means ± SEM from three
or more independent experiments. Statistical analysis was
performed by using one-way ANOVA and the DunnettB
D
mast cells. RBL-2H3 mast cells (A) and BMMCs (B) were incubated
th medium. The IgE-primed mast cells were stimulated by antigen
asured as described in the “Methods” section. (C) RBL-2H3 cells were
ted cells were washed five times with PIPES buffer, degranulation of
ERD for 8 h and the cell viability, then, was measured as described in
nts are shown here. Asterisks indicate significant differences from the
r.
AB
Figure 2 The effect of LERD on the expression and secretion of
TNF-α and IL-4. (A) The IgE-primed RBL-2H3 cells (1 × 106 cells/well)
were stimulated by the antigen for 15 min for the assay of TNF-α
and IL-4 mRNA by RT-PCR. The representative images (upper panel)
and densitometric data (lower panel) from three independent
experiments are shown. (B) The IgE-primed RBL-2H3 cells (1 × 106
cells/well) were stimulated by antigen for 8 h and the secretion
of TNF-α and IL-4 was then measured by ELISA. The values are
expressed as the mean ± SEM from three independent experiments.
Asterisks indicate significant differences from the controls, *P < 0.05
and **P < 0.01. PP2 is a general Src family kinase inhibitor.
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were performed with SigmaStat software (Systat Software
Inc., Point Richmond, CA, USA).
Results
The effects of LERD and other herbal extracts on
antigen-stimulated degranulation in mast cells
Mast cells have secretary granules containing allergic
mediators such as histamine and various proteases that
cause allergic symptoms [20]. Thus, the effects of ap-
proximately 100 herbal extracts on the degranulation of
mast cells were firstly measured in RBL-2H3 mast cells.
The extracts from Vitex rotundifolia, Prunus sargentii,
Lycoris aurea, Hydrangea serrata for. acuminata, Prunus
takesimensis, Clintonia udensis, and Rhamnus davurica
significantly inhibited degranulation (>50%) at a con-
centration of 100 μg/ml in RBL-2H3 cells (Table 1).
Among them, LERD most potently suppressed degra-
nulation, release of β-hexosaminidase, in antigen-
stimulated RBL-2H3 mast cells or BMMCs in a dose
dependent manner (Figure 1A and B). However, LERD
did not inhibit the activity of β-hexosaminidase re-
leased from mast cells (data not shown). When mast
cells were washed twice with the incubation buffer
after pretreating with LERD for 1 h, the degranulation
of mast cells was almost completely recovered (Figure 1C),
indicating that the effect of LERD on mast cell activation
was reversible. Notably, no effect on the viability of
mast cells was observed by LERD at the experimental
doses (Figure 1D).
Effect of LERD on the expression and secretion of
inflammatory cytokines
In addition to degranulation in mast cells, mast cells
also secrete various inflammatory cytokines. Among
them, TNF-α and IL-4 are secreted in antigen- stimu-
lated cells. Therefore, we measured the expression
levels of TNF-α and IL-4 by RT-PCR. As shown in
Figure 2A, the expression of TNF-α and IL-4 was dose-
dependently suppressed in antigen-stimulated mast
cells. The secretion levels of TNF-α and IL-4 were also
analyzed by ELISA assay. The secretion of TNF-α and
IL-4 was consistently inhibited in a dose dependent
manner (Figure 2B).
Effect of LERD on activations of signaling molecules by
antigen
Next, to ascertain the mechanism of the LERD action,
we investigated which intracellular signaling mole-
cules were affected by LERD treatment. It is well
known that Syk and its direct substrate protein LAT
pathway is a pivotal signaling cascade for mast
cell activation [12]. LERD suppressed the activation
of Syk and LAT in RBL-2H3 cells and BMMCs(Figure 3). At a dose of 30 μg/ml, the inhibition
was obvious and was nearly complete at 100 μg/ml
(Figure 3). Next, we also studied MAP kinase signal-
ing pathway which is generally accepted that three
typical MAP kinases are critical for the production of
inflammatory cytokines from mast cells [21,22]. In
this experiment, LERD significantly reduced the acti-
vation of ERK1/2, p-38 and JNK in a dose dependent
manner (Figure 3).
Figure 3 LERD inhibits the activation of Syk and Syk-mediated
downstream signaling molecules. The RBL-2H3 cells (upper panel)
or BMMCs (lower panel) were incubated overnight with 50 ng/ml
IgE and cells were then stimulated with 25 ng/ml antigen with or
without LERD for 7 min. Cell lysates were subjected to immunoblot
analysis with specific antibodies to detect phosphorylated or total
proteins. Representative immunoblotting images are shown from three
independent experiments. PP2 is a general Src family kinase inhibitor.
A
B
Figure 4 LERD inhibits the activity of Fyn, but not Lyn. RBL-2H3
cells (1 × 107 cells/dish) were incubated with 50 ng/ml IgE for
overnight and then stimulated with 25 ng/ml antigen for 7 min
after pre-incubating with or without LERD for 1 h. (A) Cell lysates
were subjected to immunoblot analysis with specific antibodies
to detect each FcεRI subunit. Representative immunoblotting
images are shown from three independent experiments. (B) Fyn
or Lyn was immunoprecipitated from the cell lysates and the
immunoprecipitates were incubated in the kinase assay buffer at
room temperature for 40 min and the activity was measured as
described in the “Methods” section. The values are expressed as
the mean ± SEM from three independent experiments. Asterisks
indicate significant differences from the controls, *P < 0.05 and
**P < 0.01. PP2 is a general Src family kinase inhibitor.
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antigen-stimulated mast cells
Several lines of evidence suggest that Lyn is the initially
activated tyrosine kinase in antigen-stimulated mast
cells. The aggregation of IgE-high affinity receptor (FcεRI)
by antigen initially leads to the activation of Lyn for down-
stream signaling molecules [12]. Another tyrosine kinase,
Fyn, is also activated in mast cells by antigen for a comple-
mentary pathway to stimulate full activation of mast cells
[23]. LERD did not show any suppressive effect on the
expressions of FcεRI subunits (Figure 4A). Next, we tested
whether LERD suppressed the upstream tyrosine kinases
of Syk, Lyn, or Fyn in the cells. As shown in Figure 4B,LERD inhibited activation of Fyn, but not Lyn, in a dose
dependent manner.
Effect of LERD on passive cutaneous anaphylaxis (PCA) in
mice
To determine the anti-allergic effect of LERD in vivo,
a PCA model was used in BALB/c mice. Histological
analysis was further performed to check whether LERD
inhibited mast cell degranulation in mouse ear tissues.
The PCA responses were successfully induced by the
injection of IgE/antigen in mice. LERD significantly
inhibited the response in a dose dependent manner
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Figure 5 LERD suppresses passive cutaneous anaphylaxis in vivo. An IgE (0.5 μg) was intradermally injected into the mouse ear. After 24 h,
an injection of 250 μg antigen in 4% Evans blue PBS solution was administered into the mouse tail vein. The LERD was orally administered 1 h
before the treatment of the antigen. The mouse was euthanized 1 h after the antigen challenge, and the ear was then removed for measurement of
the amount of dye extravasated (A) or histological changes (B) by antigen treatment. (A) Representative photographs of ears after PCA (upper panel)
and quantitative data for ear-tissue content of Evans blue (lower panel). (B) The ear tissues were prepared and stained with toluidin blue for histological
examination as described in the “Methods” section. Representative images (upper panel) and the percentage of degranulated mast cells in ear skin
sections (lower panel) are shown: arrows indicate mast cells. bar, 50 μm. The values are expressed as the mean ± SEM from three independent
experiments. *P < 0.05 and **P < 0.01.; C.Z., cetirizine.
Kim et al. BMC Complementary and Alternative Medicine  (2015) 15:80 Page 9 of 11LERD suppressed the degranulation of tissue mast cells
by antigen (Figure 5B). These results suggested that
LERD has an anti-allergic effect in vivo through the in-
hibition of mast cells.
Discussion
Allergic diseases such as asthma, allergic rhinitis, and
atopic dermatitis are on the rise, particularly, in devel-
oped countries. It has been generally accepted that
when people who are skewed to Th2 intake or come
into physical contact with a specific allergen, they suf-
fer from allergic symptoms. A large body of evidence
suggests that mast cell is a key player of acute and
chronic allergic inflammation in allergic diseases [20].
In this context, stimulation of mast cells by antigen re-
sults in the release of a variety of mediators such as
histamine and an array of inflammatory cytokines that
cause allergic symptoms [6,12]. Therefore, the regula-
tion of mast cells is one of the potential therapeutic
approaches for the development of allergy medication.
In this study, we demonstrated for the first time thatLERD suppresses mast cell-mediated PCA in mice by
inhibiting the activation of the Fyn/Syk signaling path-
way in mast cells.
Mast cells play a critical role in immune response
when a foreign antigen infiltrates a human body. When
mast cells are stimulated by antigen, they release pre-
formed granule-associated mediators, such as histamine,
serotonin, and β-hexosaminidase, eicosanoids, inflamma-
tory cytokines, and chemokines [24,25]. These mediators
lead to certain pathophysiological changes and tissue re-
modeling for various allergic symptoms.
The effects of drugs are generally reversible in a
human body. After a certain period following the
administration of a drug, the function of drug-target
molecule returns to normal functioning status. If the
action of a drug, on the other hand, is irreversible, its
effect persists until the body generates additional pro-
tein. Therefore, it is critical to check at the early
stage of the drug development whether a candidate
is reversible. The inhibition of LERD on mast cell ac-
tivation was reversible (Figure 1C), suggesting that
Figure 6 LERD inhibits the activation of Fyn for the
antigen-mediated activation of mast cells. LERD suppresses the
activation of Fyn and Fyn/Syk-mediated downstream signaling
molecules for the release of various allergic mediators in
antigen-stimulated mast cells.
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activations of signaling molecules in antigen-stimulated
mast cells.
Accumulating evidence from mice and humans has ar-
gued that Th2 cytokines such as IL-4, IL-5, and IL-13 are
contributors to allergic responses [26]. Mast cells secrete
the cytokines. Apart from these Th2 cytokines, TNF-α, one
of the critical inflammatory cytokines, is also secreted from
mast cells [12]. In this study, LERD suppressed the expres-
sion and secretion of IL-4 and TNF-α in antigen-stimulated
mast cells (Figure 2). The results further suggested that
LERD may have a therapeutic potential in cytokine-
associated allergic symptoms in allergic patients.
In the atopic environment, mast cells are activated by
binding antigen to the IgE that is bound to its multi-
meric receptor, FcɛRI. The aggregation of FcɛRIs leads
to the phosphorylation of tyrosine residues of the
ITAMs of FcɛRI by Lyn and, subsequently, activation of
Syk, a pivotal signaling molecule for mast cell activation
by the antigen. Syk is essential for the activation of many
downstream signaling molecules including LAT adaptor
protein. The activation of Syk is also critical for the
activation of Akt and three typical MAP kinases (ERK1/2,
p38, and JNK). In such a manner, mast cells are activated
to release an array of allergic mediators [12]. In this study,
LERD inhibited activation of Syk and LAT in antigen-
stimulated mast cells (Figure 3), suggesting that its inhib-
ition of Syk activation was a key mechanism of LERD.
Fyn is an essential signaling molecule for full activa-
tion of antigen-stimulated mast cells. The activation of
Fyn is critical for the activation of the Gab2/PI3-K/Akt
pathway [23]. In other reports, Fyn is also important for
the activation of Syk [11,27]. Of note, our study found
that LERD inhibited only the activity of Fyn, not Lyn, in
antigen-stimulated mast cells (Figure 4B), suggesting
that LERD suppressed the activation of Fyn and Fyn/
Syk-mediated downstream signaling molecules.
Anaphylaxis is an allergic response that is remarkably
dangerous and acute as it can cause death due to as-
phyxiation. Systemic or local anaphylaxis may occur
when the exterior allergens such as insect venom, food,
and pollen infiltrate the allergic patient’s body [28]. The
reactions cause the release of inflammatory mediators
and cytokines from mast cells and basophils [29]. To
confirm the anti-allergic effect of LERD in animal model,
we utilized IgE-mediated PCA mice. In the mice, LERD re-
markably suppressed the anaphylactic responses (Figure 5A)
and degranulation of mast cells in ear (Figure 5B). Taken
together, the results demonstrated that LERD has an
anti-allergic effect in vivo.
Conclusions
Our results demonstrated for the first time that LERD
suppresses degranulation and cytokine production inantigen-stimulated mast cells and, furthermore, inhibits
IgE-mediated allergic responses in mice. Mechanically,
LERD suppresses the activation of Fyn/Syk pathway and
its downstream signaling molecules to supress secretion
of allergic mediators in mast cells (Figure 6). Although
further comprehensive studies for bioavailability, tox-
icity, and active components of LERD are required for
the development of drug, our finding suggested that
LERD may be a useful herbal extract for human allergic
diseases.
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